Regeneron Pharmaceuticals Inc. buy PortfolioRatio12
Start price
13.02.25
/
50%
€644.20
Target price
13.03.25
-
Performance (%)
-2.02%
End price
14.03.25
€631.20
Summary
This prediction ended on 14.03.25 with a price of €631.20. With a performance of -2.02%, the BUY prediction by PortfolioRatio12 finished with a loss. Dividends of €0.84 are taken into consideration when calculating the performance. PortfolioRatio12 has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -0.340% | -0.340% | 22.275% |
| iShares Core DAX® | 2.992% | 3.220% | 4.271% |
| iShares Nasdaq 100 | -1.584% | -3.172% | 24.749% |
| iShares Nikkei 225® | -2.254% | -9.924% | 43.518% |
| iShares S&P 500 | -0.009% | 1.641% | 20.967% |
Comments by PortfolioRatio12 for this prediction
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von PortfolioRatio12 gewählte maximale Laufzeit wurde überschritten